CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response

@article{Haapaniemi2018CRISPRCas9GE,
  title={CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response},
  author={Emma M. Haapaniemi and Sandeep K Botla and Jenna Persson and Bernhard Schmierer and Jussi Taipale},
  journal={Nature Medicine},
  year={2018},
  volume={24},
  pages={927-930}
}
Here, we report that genome editing by CRISPR–Cas9 induces a p53-mediated DNA damage response and cell cycle arrest in immortalized human retinal pigment epithelial cells, leading to a selection against cells with a functional p53 pathway. Inhibition of p53 prevents the damage response and increases the rate of homologous recombination from a donor template. These results suggest that p53 inhibition may improve the efficiency of genome editing of untransformed cells and that p53 function should… Expand
No apparent p53 activation in CRISPR-engineered gene-edited rabbits.
  • Tao Zhang, Jinze Li, Tian Wang, Feiyu Zhao, Tingting Sui
  • Medicine
  • Journal of cellular and molecular medicine
  • 2021
TLDR
This study provides the first evidence that no apparent p53 expression changes in those rabbits generated by Cas9 or BE-edited, suggesting that p53 may not need to consider for application in gene-edited animals. Expand
Rapid genome editing by CRISPR-Cas9-POLD3 fusion
TLDR
It is concluded that while DNA repair protein fusions to Cas9 can improve HDR CRISPR editing, most need to be optimized to the particular cell type and genomic site, highlighting the diversity of factors contributing to locus-specific genome editing outcomes. Expand
CAS9 is a genome mutator by directly disrupting DNA-PK dependent DNA repair pathway
TLDR
It is reported that CAS9 protein can function as a genome mutator independent of any exogenous guide RNA in human cells, promoting genomic DNA double-stranded break (DSB) damage and genomic instability. Expand
CRISPR/Cas9 Treatment Causes Extended TP53-Dependent Cell Cycle Arrest In Human Cells
TLDR
It is concluded that CRISPR/Cas9 treatment induces a cell cycle arrest dependent on functional TP53 as well as Cas9 DNA binding and cleavage and suggests that transient inhibition of TP53 may increase genome editing efficiency in primary and TP53+/+ cell lines. Expand
Parallel CRISPR-Cas9 screens clarify impacts of p53 on screen performance
TLDR
This work demonstrates that although functional p53 status negatively affects identification of significantly depleted genes, optimal screen design can nevertheless enable robust screen performance. Expand
CRISPR enriches for cells with mutations in a p53-related interactome, and this can be inhibited
TLDR
It is shown that cells deficient in p53, as well as in genes of a core CRISPR-p53 tumor suppressor interactome, are enriched in a cell population whenCRISPR is applied, and that transient p53 inhibition suppresses the enrichment of cells with these mutations. Expand
Parallel CRISPR-Cas9 screens clarify impacts of p53 on screen performance
TLDR
This work demonstrates that although functional p53 status negatively affects identification of significantly depleted genes, optimal screen design can nevertheless enable robust screen performance. Expand
“Global Transcriptional Response to CRISPR/CAS9-AAV6 Based Genome Editing” Matches Transcriptional Response to Specific Small Molecule Perturbations
TLDR
Using a CD34+ hematopoietic and progenitor stem cell model, differentially expressed genes enriched for immune, stress and apoptotic processes following treatment with a CRISPR/Cas9-AAV6 genome-editing system are observed. Expand
CRISPR/Cas9 treatment causes extended TP53-dependent cell cycle arrest in human cells
TLDR
It is concluded that CRISPR/Cas9 treatment induces a cell cycle arrest dependent on functional TP53 as well as Cas9 DNA binding and cleavage, and transient inhibition of TP53 may increase genome editing recovery in primary and TP53+/+ cell lines. Expand
Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing
TLDR
It is shown that CRISPR-Cas9 editing generates structural defects of the nucleus, micronuclei and chromosome bridges, which initiate a mutational process called chromothripsis, which is a previously unappreciated on-target consequence of CRISpr- Cas9-generated DSBs. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 19 REFERENCES
Inhibition of 53BP1 favors homology-dependent DNA repair and increases CRISPR-Cas9 genome-editing efficiency
TLDR
expression of one variant, named i53 (inhibitor of 53BP1), in human and mouse cells, blocked accumulation of 53 BP1 at sites of DNA damage and improved gene targeting and chromosomal gene conversion with either double-stranded DNA or single-strander oligonucleotide donors by up to 5.6-fold. Expand
Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype
TLDR
This study indicates that CRISPR-Cas9–mediated genome editing is possible in adult animals and has potential for correction of human genetic diseases. Expand
Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining
TLDR
This work targeted DNA ligase IV, a key enzyme in the NHEJ pathway, using the inhibitor Scr7, and increased the efficiency of HDR-mediated genome editing, using Cas9 in mammalian cell lines and in mice for all four genes examined. Expand
MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens
TLDR
Model-based Analysis of Genome-wide CRISPR/Cas9 Knockout (MAGeCK) demonstrates better performance compared with existing methods, identifies both positively and negatively selected genes simultaneously, and reports robust results across different experimental conditions. Expand
53BP1 Integrates DNA Repair and p53-Dependent Cell Fate Decisions via Distinct Mechanisms
TLDR
It is revealed that 53BP1 stimulates genome-wide p53-dependent gene transactivation and repression events in response to ionizing radiation (IR) and synthetic p53 activation. Expand
Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA
TLDR
By rationally designing single-stranded DNA donors of the optimal length complementary to the strand that is released first, this work increases the rate of HDR in human cells when using Cas9 or nickase variants to up to 60%. Expand
Genome-wide screen of cell-cycle regulators in normal and tumor cells identifies a differential response to nucleosome depletion
TLDR
It is found that tumor and normal cells are differentially sensitive to loss of the histone genes transcriptional regulator CASP8AP2, indicating that nucleosome depletion is sensed in normal cells via a DNA-damage -like response that is defective in tumor cells. Expand
Resolving systematic errors in widely-used enhancer activity assays in human cells
TLDR
All episomal enhancer activity assays in mammalian cells are overcome by employing the ORI as core promoter and by inhibiting two IFN-I-inducing kinases, enabling genome-wide STARR-seq screens in human cells. Expand
CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells
TLDR
These preclinical studies outline a CRISPR-based methodology for targeting haematopoietic stem cells by homologous recombination at the HBB locus to advance the development of next-generation therapies for β-haemoglobinopathies. Expand
CRISPR/Cas9 screening using unique molecular identifiers
TLDR
Random Sequence Labels (RSLs) are incorporated into the guide library, which act as unique molecular identifiers (UMIs) to allow massively parallel lineage tracing and lineage dropout screening. Expand
...
1
2
...